Becton, Dickinson and (BDX) Q4 FY2026 Earnings Call: Guidance and Outlook
BD provided formal guidance for fiscal year 2027, projecting low single-digit revenue growth and flat operating margins as the company navigates inflationary environments and Alaris comparisons.
About Becton, Dickinson and. Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products.
Expected to be at the low end of the full-year range.
Q1 Adjusted EPS
Expected to be between $2.32 and $2.37.
Annual guidance
Revenue Growth
Low single-digit growth for the full year, with currency estimated as a headwind of about 70 basis points and an approximate 200 basis point impact from the Alaris capital comparison.
Adjusted Operating Margins
Expected to be roughly flat year-over-year.
Adjusted Tax Rate
Expected to be between 16% and 17%.
Weighted Average Shares Outstanding
Expected to be approximately 273 million.
Adjusted EPS
Expected to be in a range of $13.10 to $13.30.
Outlook
Underlying growth
Excluding the Alaris headwind, management expects mid-single-digit growth at the midpoint of guidance for fiscal 2027.
Inflation and costs
Management anticipates an inflationary environment in fiscal 2027, which will be mitigated by BD excellence initiatives, supply chain efficiencies, and pricing actions.
Tariff assumptions
Current guidance assumes tariffs generally in line with fiscal 2026 and does not include potential relief from the U.S. government partnership agreement under Section 232.
Vaccine headwinds
Vaccine headwinds are expected to dissipate entirely in fiscal 2027 and no longer be a headwind to the Biopharma Systems business.
Dombey's summary of the Becton, Dickinson and Q4 FY2026 earnings call held Nov 5, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
